Intranasal delivery of human growth hormone: Optimization of formulation
✍ Scribed by Kerstin Albertsson-Wikland; Lars Hedin; Peter Jansson; Sten Rosberg; Conny Wikström
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 669 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The clinical impact of biotechnology has been constrained by the limitations of traditional hypodermic injection of biopharmaceuticals. Microneedle patches have been proposed as a minimally invasive alternative. In this study, the translation of a dissolving microneedle patch designed f
The goal of the current study was to develop an intranasal (IN) formulation of the acetylcholinesterase inhibitor galantamine, an important therapeutic for treating Alzheimer's disease. To allow for delivering a therapeutically relevant dose, it was necessary to greatly enhance drug solubility. Vari
The transepithelial transport of biosynthetic human growth hormone (hGH) formulated with the absorption enhancers didecanoylia-phosphatidylcholine (DDPC) and a-cyclodextrin (a-CD) was studied after intranasal administration to rabbits. Plasma concentrations of the hormone were determined until 240 r
This study was aimed at investigating the potential of a new polycarbophil-cysteine (PCP-Cys)/glutathione (GSH) gel formulation to enhance the permeation of the model drug human growth hormone (hGH) across nasal mucosa in vitro and in vivo. The aqueous nasal gel contained PCP-Cys, GSH, and hGH in a